| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02501434 Details | 2022-03-04 Interventional | 2 | - | Calcium heparin Heparin Aneurysm Hemorrhage Intracranial An… Neurobehavioral… Subarachnoid He… Thrombocytopeni… Vasospasm, Intr… Aneurysmal Suba… Heparin-induced… | - - | |||
| NCT01685606 Details | 2022-03-04 Interventional | 2 | 6 | Immunomodulatin… Burkitt Lymphom… Leukemia Lymphoma Lymphoma, Large… Lymphoma, Mantl… Precursor Cell … Acute Myeloid L… Burkitts Lympho… Diffuse Large C… Mantle Cell Lym… T Cell Lymphoma… | Lack of accrual and low efficacy - | |||
| NCT01650350 Details | 2022-03-04 Interventional | 2 | 7 | Naltrexone Carcinoma, Rena… Kidney Neoplasm… Melanoma Prostatic Neopl… Prostate Cancer Renal Cancer | Study stopped 10/24/13 secondary to lack of patients/slow enrollment - | |||
| NCT01552590 Details | 2022-03-04 Interventional | 4 | 74 | Tolvaptan Ascites Hyponatremia Hyponatremia an… | - - | |||
| NCT00198328 Details | 2022-03-04 Interventional | 3 | 84 | Bleomycin Carcinoma Carcinoma, Squa… Head and Neck N… Head Neck Cance… | Enrollment was stopped based on the Data Monitoring Committee's recommendation. - | |||
| NCT00198315 Details | 2022-03-04 Interventional | 3 | 130 | Bleomycin Carcinoma Carcinoma, Squa… Head and Neck N… Head and Neck C… | Enrollment was stopped based on the Data Monitoring Committee's recommendation. - | |||
| NCT03202147 Details | 2022-03-03 Interventional | 2 | 0 | Cromolyn Sodium Cerebral Infarc… Cognitive Dysfu… Ischemia Ischemic Stroke Stroke Post-stroke Cog… | Study halted prematurely prior to initiation but potentially will resume in the future. - | |||
| NCT02462538 Details | 2022-03-03 Interventional | 1/2 | 3 | Brentuximab Ved… Imatinib Mesyla… Lymphoma Lymphoma, Large… ALK+ Anaplastic… | Due to slow recruitment, recruitment of new patients was stopped, FU was completed for enrolled
patients - | |||
| NCT04856475 Details | 2022-03-02 Interventional | 2 | 0 | Neratinib Brain Neoplasms Breast Neoplasm… Neoplasm Metast… Brain Metastase… Breast Cancer | Termination of collaboration with PUMA - | |||
| NCT04611139 Details | 2022-03-02 Interventional | 1 | 0 | Pembrolizumab Carcinoma, Endo… Endometrial Neo… Endometrial Can… Ovarian Clear C… Ovarian Endomet… SCCOHT | Salarius discontinued support - | |||
| NCT04459286 Details | 2022-03-02 Interventional | 2 | 57 | Atazanavir Sulf… Nitazoxanide Ritonavir COVID-19 Covid-19 | IDSMB recommendation - | |||
| NCT04456023 Details | 2022-03-02 Interventional | 2 | 0 | Tisagenlecleuce… Lymphoma Lymphoma, B-Cel… Lymphoma, Large… Lymphoma, Non-H… Diffuse Large B… | This study was cancelled before enrolling any patients for business related reasons. - | |||
| NCT04448834 Details | 2022-03-02 Interventional | 2 | 0 | Blinatumomab Vincristine Leukemia Leukemia, Lymph… Precursor Cell … B-cell Acute Ly… | Study not moving forward - | |||
| NCT03311269 Details | 2022-03-02 Interventional | 2 | 19 | Sodium Tetradec… Venous Insuffic… | Study was terminated for administrative reasons A total of 19 subjects were enrolled in the study. The study was terminated for administrative reasons; there were no safety or efficacy concerns. It was determined by the sponsor that the Phase 3 protocol, which is designed to closely mimic the Phase 2 protocol, would be adequate to collect safety and efficacy assessments with minor adjustments. | |||
| NCT03151304 Details | 2022-03-02 Interventional | 2 | 64 | Azacitidine Myelodysplastic… Preleukemia Syndrome | Sponsor's decision as at the completion of the primary analysis, the data were considered
mature - | |||
| NCT01455389 Details | 2022-03-02 Interventional | 1/2 | 25 | Dexamethasone Diphenhydramine Erlotinib Hydro… Promethazine Lung Neoplasms Lung Cancer | Trial terminated by sponsor after decision to evaluate combination of quaratusugene ozeplasmid
and osimertinib instead of further evaluating quaratusugene ozeplasmid and erlotinib. - | |||
| NCT00581477 Details | 2022-03-02 Interventional | 2/3 | 8 | Droxidopa Autonomic Nervo… Hypotension Hypotension, Or… Nervous System … Orthostatic Int… Primary Dysauto… Dopamine Beta-H… Orthostatic Hyp… | 1. enrollment slower than anticipated; 2. FDA approval of droxidopa so no longer need to treat
patients on research basis; 3. personnel who were primarily responsible for the study are no
longer at Vanderbilt. - | |||
| NCT03739138 2018-000845-37 Details | 2022-02-28 Interventional | 1 | 30 | Pembrolizumab Neoplasms Advanced Solid … | Business Reasons - | |||
| NCT03347123 2017-001743-12 Details | 2022-02-28 Interventional | 1/2 | 11 | Ipilimumab Nivolumab Neoplasms Solid Tumors | A business decision made by Incyte after analysis of data from a sister study. - | |||
| NCT02323126 2014-003731-20 Details | 2022-02-28 Interventional | 2 | 64 | Nazartinib Nivolumab Carcinoma, Non-… Lung Neoplasms Non Small Cell … | Sponsor decision due to low patient recruitment caused by the change in the treatment landscape
of NSCLC. - |